The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interstitial lung disease associated with drug therapy
Open accessAbstract
Drug-associated interstitial lung disease (ILD) is not uncommon, with diverse patterns ranging from benign infiltrates to the potentially fatal acute respiratory distress syndrome. As acute respiratory failure due to drug-associated ILD has an unpredictable onset and rapid time course, establishing a diagnosis is often difficult. An accurate diagnosis is based on clinical, radiological (including high-resolution computed tomography) and histological manifestations, although is often only possible by exclusion. Cancer chemotherapy is commonly associated with acute disease that, on pathology, is often diffuse alveolar damage. Furthermore, a combination of drugs with or without radiotherapy can increase the risk of ILD. This article reviews treatments for non-small-cell lung cancer (NSCLC) that are associated with the development of ILD and how systematic evaluation of the possible role of these drugs in ILD is warranted. A difference between Japan and the rest of the world in reporting rates of ILD when gefitinib ('Iressa') has been used in advanced NSCLC is also discussed. However, the difference remains unexplained, leaving important epidemiological and mechanistic questions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620
“This inhibitory activity against a pathogenic mutant form of EGFR is not accompanied by meaningful wild-type EGFR inhibition, suggesting that drug tolerability may be superior to first and second generation TKIs, for which key toxicities of skin rash, diarrhea and interstitial lung disease are attributed to wild-type…”
BackgroundAndo, M., Okamoto, I., Yamamoto, N., Takeda, K., Tamura, K., Seto, T., Ariyoshi, Y., & Fukuoka, M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9866 · Cited by 362
Powell, C. A., Modi, S., Iwata, H., Takahashi, S., Smit, E. F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100554 · Cited by 270
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
Vahid, B., & Marik, P. E. (2008) · Chest · doi:10.1378/chest.07-0851 · Cited by 254
Metadata
- Authors
- Camus, P., Kudoh, S., & Ebina, M.
- Venue
- British Journal of Cancer
- Published
- 2004-08
- Volume
- 91
- Issue
- S2
- Pages
- S18-S23
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1967649543
- Cited by
- 173
- References
- 1
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.